UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~July 289, 2010

IMARX THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-33043	86-0974730
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


6860 Lexington Avenue, Suite 120 Los Angeles, CA		90038
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (323) 790-1717

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3 5.~~02 Unregistered~~07 Submission ~~Sales~~of Matters to a Vote of ~~Equity~~Security ~~Securities~~Holders.

On ~~May 28~~July 9, 2010, ~~JRT Productions Inc. (“JRT”) a company wholly-owned by Joseph Takats an officer and director of~~ ImaRx Therapeutics, Inc. (~~the~~ “~~Company~~ImaRx”) ~~and~~or ~~Red~~the ~~Cat Productions (~~“~~Red Cat~~Company”), aheld ~~company wholly-owned by Donald Scotti, an officer and director of the Company, each delivered to the Company~~ a ~~conversion~~Special Meeting ~~notice exercising their right to convert each~~ of ~~their $200,000 Promissory Notes into shares of the Company’s common stock, par value $~~Stockholders.~~0001 per share (the “Shares”).~~ ~~Pursuant~~At to the ~~terms~~special ~~of the Promissory Notes the conversion price was $0.00783 per share~~meeting, ~~calculated as~~ the ~~average~~stockholders of ImaRx ~~the~~approved ~~three trading prices for~~ the ~~Shares~~reincorporation ~~on the three trading days preceding the date~~ of ~~delivery of~~ the ~~conversion notice. As a result, the~~ Company ~~will issue 25,542,784 shares of its common stock to JRT and 25,542,784 shares of its common stock to Red Cat following an amendment to the Company's certificate of incorporation resulting~~ in ~~an increase in~~ the ~~authorized~~State ~~number~~ of ~~shares~~Nevada ~~of common stock of the Company. The amendment is expected to be approved~~ by the following Company's stockholders in July 2010. The Promissory Notes were issued by the Company to JRT and Red Cat in connection with the acquisition of Sycamore Films, Inc. by the Company that closed on May 14, 2010. The Company expects to rely on the exemptions from registration provided for under Section 4(2) of the Securities Act of 1933, as amended, and Regulation D when issuing the Shares.vote:

Votes For:		77,114,506
Votes Against:		6000
Abstentions:		759
Broker Non-Votes:		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2010		IMARX THERAPEUTICS, INC.
Date: July 14, 2010	IMARX THERAPEUTICS, INC.
	By:	~~By:~~/s/ Edward Sylvan	~~/s/ Edward Sylvan~~
		Edward Sylvan	~~Edward Sylvan~~
		Chief Executive Officer	~~Chief Executive Officer~~

Filing Compare · IMARX THERAPEUTICS INC